Zemuron Side Effects
Generic name: rocuronium
Medically reviewed by Drugs.com. Last updated on Dec 2, 2023.
Note: This document contains side effect information about rocuronium. Some dosage forms listed on this page may not apply to the brand name Zemuron.
Applies to rocuronium: intravenous solution.
Serious side effects of Zemuron
Along with its needed effects, rocuronium (the active ingredient contained in Zemuron) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking rocuronium:
Rare
- Cough
- difficulty with breathing
- dizziness
- fainting
- fast, slow, or irregular heartbeat
- noisy breathing
- swelling at the injection site
- tightness in the chest
Incidence not known
- Difficulty with swallowing
- hives, itching, or skin rash
- muscular pain, tenderness, wasting, or weakness
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- unusual tiredness or weakness
For Healthcare Professionals
Applies to rocuronium: intravenous solution.
Cardiovascular
Uncommon (0.1% to 1%): Arrhythmia, abnormal electrocardiogram, tachycardia
Rare (0.01% to 0.1%): Hypotension, hypertension
Very rare (less than 0.01%): Circulatory collapse and shock, flushing[Ref]
Dermatologic
Rare (0.01% to 0.1%): Injection site edema, pruritus
Very rare (less than 0.01%): Angioneurotic edema, urticaria, rash, erythematous rash[Ref]
Gastrointestinal
Uncommon (0.1% to 1%): Nausea, vomiting[Ref]
Hypersensitivity
Very rare (less than 0.01%): Hypersensitivity, anaphylactic reaction, anaphylactoid reaction, anaphylactic shock, anaphylactoid shock[Ref]
Respiratory
Uncommon (0.1% to 1%): Asthma (bronchospasm, wheezing, or rhonchi), hiccup
Very rare (less than 0.01%): Bronchospasm
Postmarketing reports: Increased pulmonary vascular resistance[Ref]
Local
Rare (less than 0.1%): Injection site pain, injection site reaction[Ref]
Musculoskeletal
Rare (less than 0.1%): Prolonged neuromuscular block
Very rare (less than 0.01%): Muscular weakness
Frequency not reported: Residual paralysis, myopathy[Ref]
Nervous system
Very rare (less than 0.01%): Flaccid paralysis[Ref]
Other
Uncommon (0.1% to 1%): Drug ineffective, drug effect/therapeutic response decreased, drug effect/therapeutic response increased
Frequency not reported: Malignant hyperthermia[Ref]
More about Zemuron (rocuronium)
- Check interactions
- Compare alternatives
- Latest FDA alerts (2)
- Dosage information
- During pregnancy
- Drug class: neuromuscular blocking agents
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
References
1. Product Information. Zemuron (rocuronium). Organon. 2001;PROD.
2. Cerner Multum, Inc. UK Summary of Product Characteristics.
3. Pharmaceutical Society of Australia. APPGuide online. Australian prescription products guide online. http://www.appco.com.au/appguide/default.asp 2006.
4. Product Information. Rocuronium Bromide (rocuronium). Hospira Inc. 2019.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.